AND EXCHANGE COMMISSION
to Section 13 or 15(d) of the Securities Exchange Act of 1934
of report (date of earliest event reported): January 24, 2020
PHARMACEUTICALS HOLDING CORP.
name of registrant as specified in its charter)
or Other Jurisdiction
Madison Avenue, Suite 1608, New York, New York 10022
of principal executive offices) (Zip Code)
telephone number, including area code: (212) 980-9155
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§
230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
growth company ☐
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
registered pursuant to Section 12(b) of the Act:
of each class
of each exchange on which registered|
NASDAQ Global Market|
January 24, 2020, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced the successful completion of a fed-fasting
and dose proportionality study of TNX-102 SL. A copy of the press release discussing this matter is filed as Exhibit 99.01, and
incorporated by reference in, this report.
Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including
those relating to the Company’s product development, clinical trials, clinical and regulatory timelines, market opportunity,
competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and
other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates,
forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.
statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,”
“intend,” “plan,” “believe,” “estimate,” “potential,” “predict,”
“project,” “should,” “would” and similar expressions and the negatives of those terms. These
statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other
factors which may cause actual results, performance or achievements to be materially different from any future results, performance
or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s
filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking
statements, which speak only as of the date of this Current Report on Form 8-K. The Company undertakes no obligation to publicly
update any forward-looking statement, whether as a result of new information, future events or otherwise.
Statements and Exhibits.|
release of Tonix Pharmaceuticals Holding Corp., dated January 24, 2020 |
to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
||TONIX PHARMACEUTICALS HOLDING
|Date: January 24, 2020
||Chief Executive Officer|